Deanol for ADHD
A few decades ago, Deanol was used as an ADHD medication.12 A daily dose of 300 mg in the morning was recommended for the first three weeks (= until the onset of action) and then a maintenance dose of 100 to 300 mg daily.3
We do not consider the following results to be particularly impressive, but they cannot be completely dismissed, especially with regard to hyperactivity.
In our opinion, despite its relatively low Effect size (compared to AMP and MPH), Deanol could, due to its low risk of side effects (although this is likely to be relativized at higher and thus more effective doses) at least
- if MPH, AMP, ATX and guanfacine are ineffective
- in case of intolerance to MPH, AMP, ATX and guanfacine (e.g. loss of appetite)
- for weaker cases
be worth a second look.
Since medical clearance is mandatory before the first intake due to the considerable risk of contraindications and side effects in some cases (self-medication experiments are dangerous!), a longer waiting time for the adjustment to MPH or AMP should barely be considered a serious reason. This applies all the more in view of the long time it takes for the drug to take effect (3 weeks). In practice, bridging the use of Deanol until dosing with MPH or AMP is only possible if accompanied by a GP, while waiting for dosing by a psychiatric specialist. This GP would have to be very committed, as deanol has completely disappeared from current prescribing practice and no doctor is likely to have any experience of it. The following collection of many relevant studies and findings on deanol could help here.
After all, Deanol is not classified as a BtM and is freely available as a dietary supplement. One study reports that it does not inhibit appetite, which would be a major advantage over other stimulants. However, the risks and contraindications should be carefully considered. It is also completely unclear how long the effect of a single dose of Deanol lasts. The fact that the onset of action can take 3 weeks opens up the cautious hope of an all-day effect, as is the case with other drugs with such a long latency to onset of action. On the other hand, the long latency of action massively increases the difficulty of dosing.
- 1. Preparations
- 2. Synonyms
- 3. Pathways of action of Deanol
- 4. Deanol for ADHD
- 5. Deanol for other disorders
- 6. Interactions, contraindications and side effects
1. Preparations
Monopreparations: Germany: Risatarun. Russia: Nooclerin. US. Deaner.
Deaner (deanol p-acetamidobenzoate) from Riker Laboratories was a prescription drug in the USA for 20 years and was withdrawn from the market in 1983.4 Risatarun is also no longer available.
According to a study conducted in an American clinic between 1956 and 1960, deanol was the most frequently prescribed first drug (ahead of chloropromazine, diamine (captodiamine), meprobamate and imipramine).5 Deanol was used for a wide range of disorders6
Deanol is still freely available as a dietary supplement. The maximum recommended daily dose for adults is 240 mg.
Combination preparations with deanol are also available (Switzerland: Pharmaton Vital Geriavit; Germany: Vita Gerin; the package leaflet does not state this, however, but refers to choline tartrate). However, at 40 mg, these contain significantly less than the daily doses of deanol previously tested for ADHD. Due to the other ingredients, we strongly advise against taking several doses of the combination preparations.
Centrophenoxine (meclofenoxate)
Centrophenoxine (meclofenoxate; the p-colorophenoxyacetic acid ester of deanol; f-dimethylaminoethyl-#-chlorophenoxyacetate hydrochloride) is a stimulant and banned doping agent that is degraded to deanol and deanol-N-oxide.7 It is no longer an approved drug for treating the symptoms of senile dementia and Alzheimer’s disease and is on the list of substances whose export is monitored in Germany as it can potentially be used to manufacture chemical weapons.8
Centrophenoxine increased the synthesis rates of total and polyA+ RNA (mRNA) in the cerebral cortex of female 26-month-old CFY rats to the level of 1.5-month-old rats. The effect was attributed to the radical scavenging function of deanol, which was incorporated into the nerve cell membrane by centrophenoxine.9 The radical scavenging function of deanol was also observed in other studies.10
Centrophenoxine reaches the brain immediately after intravenous administration. There it is hydrolyzed to p-chlorophenoxyacetic acid and dimethylaminoethanol. The acid is excreted from the brain within a few hours after administration. The alcohol portion is hydrolyzed to
- free dimethylaminoethanol (highest brain level 5 minutes after administration), this is metabolized to
- Phosphoryldimethylaminoethanol is phosphorylated (highest brain level after 20 minutes), which in turn is converted into
- Phosphatidyldimethylaminoethanol (maximum after 4 hours).11
2. Synonyms
Synonyms of Deanol
Synonyms of deanol:12 2-(dimethylamino)ethanol, (2-hydroxyethyl)dimethylamine, (dimethylamino)ethanol, (N,N-dimethylamino)ethanol, 2-(dimethylamino)ethanol, 2-(dimethylamino)ethyl alcohol, 2-(N,N-dimethylamino)ethanol, Amietol M 21, Aminoalcohol 2mabs, Bimanol, DMAE, DMEA, Dabco DMEA, Deanol, DeuAdd MA 95, Dimethol, Dimethyl(2-hydroxyethyl)amine, Dimethyl(hydroxyethyl)amine, Dimethylethanolamine, Dimethylmonoethanolamine, Jeffcat DMEA, Kalpur P, Lupragen N 101, MA 95, N,N-Dimethyl(2-hydroxyethyl)amine, N,N-dimethyl-2-aminoethanol, N,N-dimethyl-2-ethanolamines, N,N-dimethyl-N-(ß-hydroxyethyl)amines, N,N-dimethyl-ß-hydroxyethylamines, N,N-dimethylethanolamines, N-(2-hydroxyethyl)-N,N-dimethylamines, N-(2-hydroxyethyl)dimethylamines, NSC 2652, Niax DMEA, Norcholine, Nooclerin, PC CAT DMEA, Propamine A, Rexoline, Risatarun, T 80, Tegoamine DMEA, Texacat DME, Texacat DMEA, Thancat DME, ß-(Dimethylamino)ethanol, ß-Dimethylaminoethyl alcohol, ß-Hydroxyethyldimethylamine, N-methyl-sarcosinol13
3. Pathways of action of Deanol
Deanol acts as a stimulant when administered chronically.141516 While amphetamine has an immediate stimulating effect, this effect is delayed with deanol and appears to occur via pathways that are subject to saturation17
Deanol crosses the blood-brain barrier. However, only small amounts enter the brain in the first 5 minutes, while a higher level is reached in the brain over 24 hours6
How deanol relates to choline and acetylcholine is still unclear.
Deanol is a close structural analog of choline, an essential nutrient, but18 does not completely replace it.19
Three possibilities are described for the mode of action of Deanol:20
-
Deanol could be a precursor of choline and thus of acetylcholine1521 15 22 whereby the acetylcholine could then be responsible for a stimulating effect.
- This is contradicted by
- That deanol did not increase the total acetylcholine content in the rat brain2324
- That deanol could not prevent damage from a low-choline diet in a choline-dependent mouse model19
- However, others report increased choline levels and only with very high danol administration also increased acetylcholine levels in the brains of the damaged rat pups2526
- However, since deanol inhibits the transport of choline through the blood-brain barrier, this is not a compelling argument against deanol as a precursor of choline
- Deanol increased the choline content in the CNS, but was only half as effective as centrophenoxine (meclofenox), which dramatically increased the choline level in the CNS of rats. In the hippocampus, this increase in choline content was accompanied by a new, increased acetylcholine (ACh) level. No such coupling was observed in the striatum or parietal cortex. The changes in choline levels were probably mainly extracellular. Despite the changes in choline and ACh levels, no consistent changes in ACh turnover were measured.27
- Deanol increases the choline level in the blood28
- However, an increase in choline levels in the brain could fail because deanol competes with choline transport at the blood-brain barrier29
- A study showing that administration of deanol increased acetylcholine levels in the striatum of rats suggests that acetylcholine levels may be limited by the amount of the precursor deanol30
- Deanol inhibits the uptake of choline into the brain, as it binds five to 10 times more strongly to the transporters of the blood-brain barrier than choline.31323334 However, the choline-blood-brain barrier inhibition by deanol is much weaker than by hemicholinium-3.35
- Deanol i.V. or orally increased choline, but not acetylcholine in the brain of rats28
- Deanol increased choline in kidney and liver36
- A recent study found no evidence that deanol alters the absorption and distribution of choline, or that deanol is converted to choline in vivo.18
- A low-choline diet did not reduce acetylcholine levels37
- Deanol increased acetylcholine levels in the brain of rodents only in the striatum and only at high doses (900 mg / kg injected into the abdomen)26
- This is contradicted by
-
Deanol could act at the cholinoceptive receptor sites due to its structural similarity to acetylcholine
- This is contradicted by the fact that atropine does not block the central vasomotor stimulating effect of deanol, while the effect of acetylcholine and carbachol is blocked by atropine
- However, another study reported that atropine temporarily weakened the effect of deanol38
-
Deanol could act on receptors other than cholinoceptive receptors to produce its stimulatory effect, and instead have a direct stimulatory effect on the vasomotor center
-
Deanol acted on cerebral cortex neurons like acetylcholine39
-
Deanol is a radical scavenger.10
-
Deanol alleviates the exploratory hyperactivity resulting from intermittent postnatal hypoxia in the rat (2nd-10th day of life after birth), while piracetam even eliminates it. The deanol was administered to the mothers (from the 12th day of gestation) and to the newborns (from birth to the 10th postnatal day of life). The perinatal administration of deanol (unlike piracetam) reduces the consequences of postnatal oxygen deficiency in terms of motor activity and dopamine release in adult animals.40
Further pathways of action of Deanol
- Single and repeated administration of neuroleptics causes a dose- and time-dependent hypersensitivity to dopamine agonists such as apomorphine and methylphenidate. Deanol does not alter this in the hypersensitivity phase.41
- In vitro, deanol causes an increased incorporation of [3H]palmitic acid into the corresponding phospholipid (phosphatidyl-N-methylethanolamine or phosphatidyl-N,N-dimethylethanolamine) in cells. In these cells, bradykinin causes increased [3H]phosphatidylethanol synthesis.42
- Deanol is an inhibitor of betaine synthesis in the kidneys43
- Deanol causes a significant increase in cholinergic phospholipids in the liver and small intestine.44
- Even intravenous administration of deanol did not induce self-administration behavior.45
- In liver cells of rats fed a low-choline diet:46
- Produced less very low density proteins than choline
- Deanol influenced the increased triacylglycerol synthesis in the choline-deficient cells just as effectively as choline.
- Deanol generates superoxide radicals at a low rate, while centrophenoxine, of which deanol is a component, is a superoxide radical scavenger with a low rate constant for this reaction, which also decreases linearly with increasing ionic strength.47
Deanol reduces embryonic choline uptake and inhibits the synthesis of sphingomyelin, phosphocholine, phosphatidylcholine and phosphatidylethanolamine.48
ADHD is linked to lipid metabolism. A cross-sectional analysis of children aged 7 to 12 with ADHD found:49
- increased sphingomyelin plasma level
- increased ceramide plasma level
- unchanged galactosylceramidase values
Deanol is a choline oxidase inhibitor.50
There are also indications that choline could be a precursor of deanol.51 Choline can be formed by methylation of deanol. However, choline is usually synthesized by converting phosphatidylethanolamine into phosphatidylcholine. Only small amounts of choline can be synthesized, which is why choline must be supplied through food4
It is possible that deanol works by preventing the breakdown of choline52
Deanol (5 mg/kg, i.v.) significantly increased the EEG output voltage in awake, free-ranging rabbits after 30 minutes. The EEG pattern showed hypersynchronization, but the animals’ behaviour was overexcited. Choline (5 mg/kg, i.v.) did not influence the effect, but doubled the time to onset of action of deanol. Atropine (1 mg/kg, i.v.) temporarily weakened the effect of deanol.38 Atropine is a competitive, reversible acetylcholine antagonist that displaces it from the muscarinic receptors (mAChR). Atropine does not act on nicotinic receptors (nAChR).
Deanol bitartrate protected rats and mice from the hepatotoxic effects of concomitantly administered paracetamol. This could be due to increased excretion of free paracetamol and its glucuronides4
Deanol administration to pregnant rats (12th day of gestation to 10th postnatal day) reduced the behavioral disturbances caused by postnatal hypoxia (motor activity in the pups; dopamine release in the striatum in the adults)4
Intravenous administration of deanol to rats resulted in the accumulation of polyunsaturated phosphatidylcholines (PC) in the liver, accompanied by a significant decrease in triacylglycerols in the liver. The accumulation of PC in deanol-infused rats was selectively attributable to three molecular species:53
- sn-1 Stearoyl/sn-2 Arachidonoyl
- sn-1 stearoyl/sn-2 linoleoyl
- sn-1 stearoyl/sn-2 docosahexanoyl)
Phosphorylated and non-phosphorylated ethanolamines (such as deanol) appear to be negative and positive regulators of insulin-induced mitogenesis, respectively, and as such act as promoters of cell survival.54
Deanol did not alter the lifespan or the formation of neoplasms (tumors) in two tumor model mouse lines after lifelong administration55
Deanol may be an impurity or metabolite of ditiline (succinylcholine chloride). Deanol has been found among the hydrolysis and thermal degradation products of diphenhydramine, which is marketed as Benadryl® and several generic over-the-counter antihistamines4
Deanol and 4-butylbenzoic acid are metabolites of the local anesthetic tetracaine hydrochloride4
Deanol decreased fibroblast proliferation, increased cytosolic calcium, altered the cell cycle and caused an increase in apoptosis in cultured human fibroblasts.56
Deanol increased DNA synthesis in fibroblasts and strongly enhanced the mitogenic effect of insulin.57
Deanol appears to be vasoactive. It causes vasorelaxation and contraction through various mechanisms such as the release of nitric oxide from the endothelium, the activation of smooth muscle K(ATP) channels and the formation of vasorelaxant prostanoids and TXA(2). This may play a role in tissue homeostasis.58
Dimethylaminoethanol pyroglutamate, which is formed from the reaction between deanol and pyroglutamic acid59
- increased extracellular choline and acetylcholine in the mPFC of rats
- improved spatial memory
- reduced the scopolamine-induced memory deficit in passive avoidance behavior
Acetylcholine binds [3H]-nicotine 3000 times more strongly than deanol and 1000 times more strongly than choline.60
Choline also inhibited the binding of the antagonist [3H]-quinuclidinyl benzilate (IC50 = 2.5 mmol/l) and the agonist [3H]-oxotremorine-M (IC50 = 165 mumol/l) to cholinergic muscarinic receptors, suggesting that choline may interact directly with brain cholinergic receptors of both the nicotinic and muscarinic types in vitro.60
4. Deanol for ADHD
Studies on the effect of deanol in children with ADHD reported:
- similar effect to stimulants15
- Hyperactivity reduced616263
- Deanol reduces the hyperactivity tripled by inorganic lead in mice for a good one and a half hours, temporarily to normal values.64 In controls not exposed to lead, the same dose of deanol led to an equally long-lasting observable behavioral arousal and stimulation of motor activity.
- Learning ability increased6162
- Reduced irritability6162
- Behavioral problems especially in hyperkinetic children with moderate unhappiness and isolation65
- Improvement in the functional capacity of children with behavioral problems (at 100 mg/day)63
- Increased attention span63
- Executive functions (organization) improved63
- Improved performance when solving puzzles and problems
- Improved motivation for learning tasks, resulting in increased learning success for rats in the water maze66
- “spectacular” results in 22 of 27 hyperkinetic children at doses up to 400 mg / day67
- Improvements in 25 of 33 children with behavioral problems (78%), deterioration in 7 of 33 (21%), with these 7 children showing a cerebral rhythm disturbance on the EEG68
- Improvement in 2 case studies with ADHD69
- no improvement compared to placebo at 100 mg deanol70
- 10 to 30 mg showed no significant changes in blood pressure, pulse rate, muscle strength, hand tremor, vital capacity, body weight or blood cholesterol levels in healthy volunteers. There were significant psychological and subjective reactions: increased muscle tone, better mental concentration, less need for sleep, calmer sleep and absence of the usual morning fatigue phase71
A review revealed:72
- the better controlled studies generally found little or no effect on ADHD
- the most promising use is for behavioral problems, particularly hyperkinetic impulse disorder and cases of poor classroom behavior and impaired attention, at doses in the range of 150 to 300 mg for children aged 6-12 years and administered for at least 3 months
A meta-analysis compared Deanol with various other ADHD medications:73
Active ingredient | Positive effect | Negative effect | Side effects | n (test subjects) |
---|---|---|---|---|
Methylphenidate | 83 % | 1 % | 14 % | n = 337 |
Amphetamine (Dexedrine, Benzedrine) | 69 % | 11 % | 12 % | n = 610 |
Chlordiazepoxide | 60 % | 17 % | 18 % | n = 237 |
Chlorpromazine | 55 % | 4 % | 25 % | n = 123 |
Deanol 50 - 150 mg | 47 % | 9 % | 7 % | n = 239 |
Reserpine | 34 % | 0 % | 1 % | n = 165 |
We notice that this study mentions a relatively low usual dosage of Deanol. Studies with better results mention higher doses. However, higher side effects are naturally to be expected.
Of the active ingredients compared, only MPH is still used today, although at that time there were no sustained release MPH preparations as they are predominantly used today. The amphetamine Benzedrine is no longer used today. Today, dexedrine (dextroamphetamine: D, CH: Attentin, USA: Adderall) has been replaced by lisdexamfetamine, whose effect in adults with ADHD is clearly superior to that of MPH, with noticeably fewer side effects.
Chlordiazepoxide is a benzodiazepine that cannot be considered for ADHD treatment due to its dependency potential.
Chlorpromazine is the oldest neuroleptic. The high side effects rule out any meaningful use in ADHD.
Reserpine is a natural alkaloid from the Indian snake root (Rauvolfia serpentina) and an antisympathotonic that inhibits dopamine and noradrenaline reuptake by blocking the VMAT2 transporter. At higher doses, however, it causes emptying of the salivary vesicles and reduces dopamine in the synaptic cleft. These effects are not desirable in the treatment of ADHD.
A placebo-controlled study of 41 to 45 children aged 6 to 12 years with ADHD found improvements with 300 to 500 mg deanol over 3 months that were statistically significant or very slightly below the significance threshold (p = 0.05 to 0.07).74
5. Deanol for other disorders
Other potential fields of application for Deanol:
- ASA: 1.8 reported improvements per reported worsening (n = 121)75 High-dose B6 and magnesium achieved 8.5 reported improvements per reported worsening (n = 318) Fenfluramine (n = 104):1.5:1. Thioridazine hydrochloride (Mellaril) (n = 724): 1.4:1.
- Depression:
- Alcohol withdrawal: reduced withdrawal symptoms, no side effects78
- Tension headache (preventive use). Deanol significantly reduced the frequency, duration and intensity of tension headaches, a regression of fatigue symptoms and a normalization of the sleep-wake rhythm.7579
- asthenic and cognitive disorders80
- Enuresis (improvement in 11 of 19 children with behavioral problems, 58%)68
- Autonomic dysfunction / dysautonomy81
- Neurasthenia in adolescents with school difficulties aged 14 to 17 years. Symptoms included autonomic disorders, decreased attention and reaction time and increased reactive anxiety, significantly decreased alpha rhythm spectrum in the occipital leads in qEEG. Deanol improved symptoms in 68.8% of subjects, but not anxiety symptoms.82
- protective effect against streptozotocin-induced diabetes mellitus and stress-induced erosive ulcer damage of the gastric mucosa when administered perorally at a dose of 250 mg/kg per 24 hours over 4 days. The effect was supported by an activation of intestinal peristalsis and an increase in blood flow in the gastric wall.83
- Deanol is said to promote lucid (conscious) dreams84
- Positive effect on visual function and the antioxidant activity of tear fluid in patients with primary open-angle glaucoma85
- anaphylactoid edema produced in the paws of rats by subplantar injection of protein, serotonin, formaldehyde or histamine were ameliorated by deanol acutely by intraperitoneal injection and, with a time delay, also by chronic oral administration. The presence of the adrenal glands was not required. Deanol was ineffective in inflammatory reactions of the cotton pellet granuloma type.86
- Skin-tightening effect with external application8788
Deanol proved to be ineffective to ineffective in:
- Tardive dyskinesia89 Tardive dyskinesia or tardive dyskinesia is a movement disorder triggered by prolonged use of dopamine antagonists (neuroleptics/antipsychotics) and persisting after their discontinuation.
- Schizophrenia (no better than placebo)90
- Alzheimer’s disease91
- Amnestic disorders92
- however, an inverted-U curve of the optimal dosage of deanol in relation to memory impairment is reported32
6. Interactions, contraindications and side effects
6.1. Interactions of Deanol
Deanol (175 to 350 mg/kg, subcutaneous) increased the effect in the CNS of rats4
- Cardiazole
- Strychnine
- Morphine
- Chlorpromazine
- Evipan
- Phenobarbital
Deanol can93
- weaken anticholinergic medication.
- interact with acetylcholinesterase (AChE) inhibitors (as used in the treatment of Alzheimer’s disease)
- interact with colinergic drugs (such as those used to treat glaucoma, Alzheimer’s disease and other diseases)
Deanol in combination with a low choline diet can have significant side effects94, as deanol inhibits the transport of choline through the blood-brain barrier.32
6.2. Contraindication of Deanol
- Deanol is contraindicated in epilepsy/convulsive disorder or bipolar Disorder. At 20 mg/day (0.084 mmol), there was a gradual increase in muscle tone and possibly an increased frequency of convulsions in susceptible individuals4
- Schizophrenia954
- Deanol must not be taken during pregnancy and breastfeeding.4 Inhibition of choline uptake and choline metabolism during neurulation caused growth retardation and developmental disorders of the neural tube and face.96
We suspect that deanol may be contraindicated in homocystinuria (excessive homocysteine levels). Deanol is an inhibitor of betaine synthesis in the kidney.43 Betaine is helpful in homocystinuria.97 At the very least, a possible influence on the betaine dosage should be discussed with the doctor.
6.3. Side effects of Deanol
Most studies speak of minor side effects, even with prolonged use.68
In humans, deanol has no effect on blood pressure, pulse rate or appetite. The side effects are minor and include headaches, constipation, insomnia, skin rash and muscle tension.3
At high doses, one study reported that 5 of 38 patients showed depressive and 3 hypomanic reactions. 7 of these 8 persons with ADHD had previously shown affective disorders.29
In a successful treatment of an essential tremor existing since early adulthood over 10 years, a pronounced developing dyskinesia syndrome, which mainly affected the orofacial and respiratory muscles, was reported (individual case report).98
An injection (not typical for medication) directly into the cerebrospinal fluid of dogs led to a slight increase in blood pressure over about 3 hours.20
Lewis JA, Young R (1975): Deanol and methylphenidate in minimal brain dysfunction. Clin Pharmacol Ther. 1975 May;17(5):534-40. doi: 10.1002/cpt1975175534. PMID: 1092513. ↥
Lewis JA, Lewis BS (1977): Deanol in minimal brain dysfunction. Dis Nerv Syst. 1977 Dec;38(12 Pt 2):21-4. PMID: 590062. ↥
Saccar CL (1978): Drug therapy in the treatment of minimal brain dysfunction. Am J Hosp Pharm. 1978 May;35(5):544-52. PMID: 26219. REVIEW ↥ ↥
Dimethylethanolamine (DMAE) [108-01-0] and Selected Salts and Esters ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥ ↥
Lowinger P, Dobie S, Reid S (1967): What happens to the psychiatric office patient treated with drugs? A follow-up study. Psychiatr Q. 1967 Jul;41(3):536-49. doi: 10.1007/BF01562615. PMID: 6078027. ↥
Miyazaki H, Kagemoto A, Ishi M, Minaki Y, Nakamura K (1971): Uptake by brain and distribution of radioactivity after intravenous administration of 14 C-labelled meclofenoxate in mice. Chem Pharm Bull (Tokyo). 1971 Aug;19(8):1681-90. doi: 10.1248/cpb.19.1681. PMID: 4399332. ↥ ↥
Krug O, Guddat S, Görgens C, Piper T, Möller T, Thevis M (2023): Determination of urinary deanol-N-oxide excretion profiles after ingestion of nutritional supplements containing deanol. Drug Test Anal. 2023 Nov-Dec;15(11-12):1312-1318. doi: 10.1002/dta.3580. PMID: 37735938. ↥
Wikipedia: Centrophenoxin german ↥
Zs-Nagy I, Semsei I (1984): Centrophenoxine increases the rates of total and mRNA synthesis in the brain cortex of old rats: an explanation of its action in terms of the membrane hypothesis of aging. Exp Gerontol. 1984;19(3):171-8. doi: 10.1016/0531-5565(84)90035-4. PMID: 6207041. ↥
Nagy I, Floyd RA (1984): Electron spin resonance spectroscopic demonstration of the hydroxyl free radical scavenger properties of dimethylaminoethanol in spin trapping experiments confirming the molecular basis for the biological effects of centrophenoxine. Arch Gerontol Geriatr. 1984 Dec;3(4):297-310. doi: 10.1016/0167-4943(84)90031-1. PMID: 6099712. ↥ ↥
Miyazaki H, Nambu K, Hashimoto M (1976): Antianoxic effect of meclofenoxate related to its disposition. Chem Pharm Bull (Tokyo). 1976 Apr;24(4):822-5. doi: 10.1248/cpb.24.822. PMID: 779990. ↥
Takagi K, Watanabe M, Saito H (1971): Studies of the spontaneous movement of animals by the hole cross test; effect of 2-dimethyl-aminoethanol and its acyl esters on the central nervous system. Jpn J Pharmacol. 1971 Dec;21(6):797-810. doi: 10.1254/jjp.21.797. PMID: 5316865. ↥
Pfeiffer CC, Jenney EH, Gallagher W, Smith RP, Bevan W Jr, Killam KF, Killam EK, Blackmore W (1957): Stimulant effect of 2-dimethylaminoethanol; possible precursor of brain acetylcholine. Science. 1957 Sep 27;126(3274):610-1. doi: 10.1126/science.126.3274.610. PMID: 13467254. ↥ ↥ ↥ ↥
GROTH DP, BAIN JA, PFEIFFER CC (1958): The comparative distribution of C14-labeled 2-dimethylaminoethanol and choline in the mouse. J Pharmacol Exp Ther. 1958 Dec;124(4):290-5. PMID: 13611630. ↥
PFEIFFER CC, GOLDSTEIN L, MUNOZ C, MURPHREE HB, JENNEY EH (1963): Quantitative comparisons of the electroencephalographic stimulant effects of deanol, choline, and amphetamine. Clin Pharmacol Ther. 1963 Jul-Aug;4:461-6. doi: 10.1002/cpt196344461. PMID: 13943065. ↥
Shipkowski KA, Sanders JM, McDonald JD, Garner CE, Doyle-Eisele M, Wegerski CJ, Waidyanatha S (2019): Comparative disposition of dimethylaminoethanol and choline in rats and mice following oral or intravenous administration. Toxicol Appl Pharmacol. 2019 Sep 1;378:114592. doi: 10.1016/j.taap.2019.05.011. PMID: 31100288; PMCID: PMC7252906. ↥ ↥
Waite KA, Vance DE (2004): Dimethylethanolamine does not prevent liver failure in phosphatidylethanolamine N-methyltransferase-deficient mice fed a choline-deficient diet. Biochim Biophys Acta. 2004 Mar 22;1636(2-3):175-82. doi: 10.1016/j.bbalip.2003.10.014. PMID: 15164765. ↥ ↥
Dhawan KN, Sinha JN, Gupta GP (1967): A study of the central vasomotor effects of 2-dimethyl aminoethanol (Deanol). Jpn J Pharmacol. 1967 Dec;17(4):648-51. doi: 10.1254/jjp.17.648. PMID: 5301355. ↥ ↥
Malanga G, Aguiar MB, Martinez HD, Puntarulo S (2012): New insights on dimethylaminoethanol (DMAE) features as a free radical scavenger. Drug Metab Lett. 2012 Mar;6(1):54-9. doi: 10.2174/187231212800229282. PMID: 22300295. ↥
Qiao D, Nikitina LA, Buznikov GA, Lauder JM, Seidler FJ, Slotkin TA (2003): The sea urchin embryo as a model for mammalian developmental neurotoxicity: ontogenesis of the high-affinity choline transporter and its role in cholinergic trophic activity. Environ Health Perspect. 2003 Nov;111(14):1730-5. doi: 10.1289/ehp.6429. PMID: 14594623; PMCID: PMC1241715. ↥
PEPEU G, FREEDMAN DX, GIARMAN NJ (1960): Biochemical and pharmacological studies of dimethylaminoethanol (deanol). J Pharmacol Exp Ther. 1960 Jul;129:291-5. PMID: 14431655. ↥
Pedata F, Wieraszko A, Pepeu G (1977): Effect of choline, phosphorylcholine and dimethylaminoethanol on brain acetylcholine level in the rat. Pharmacol Res Commun. 1977 Sep;9(8):755-61. doi: 10.1016/s0031-6989(77)80067-2. PMID: 928501. ↥
Zahniser NR, Katyal SL, Shih TM, Hanin I, Moossy J, Martinez AJ, Lombardi B (1978): Effects of N-methylaminoethanol, and N,N-dimethylaminoethanol in the diet of pregnant rats on neonatal rat brain cholinergic and phospholipid profile. J Neurochem. 1978 Jun;30(6):1245-52. doi: 10.1111/j.1471-4159.1978.tb10452.x. PMID: 670968. ↥
Zahniser NR, Chou D, Hanin I (1977): Is 2-dimethylaminoethanol (deanol) indeed a precursor of brain acetylcholine? A gas chromatographic evaluation. J Pharmacol Exp Ther. 1977 Mar;200(3):545-59. PMID: 850128. ↥ ↥
Wood PL, Péloquin A (1982): Increases in choline levels in rat brain elicited by meclofenoxate. Neuropharmacology. 1982 Apr;21(4):349-54. doi: 10.1016/0028-3908(82)90099-5. PMID: 6806676. ↥
Jope RS, Jenden DJ (1979): Dimethylaminoethanol (deanol) metabolism in rat brain and its effect on acetylcholine synthesis. J Pharmacol Exp Ther. 1979 Dec;211(3):472-9. PMID: 512912. ↥ ↥
Millington WR, McCall AL, Wurtman RJ (1978): Deanol acetamidobenzoate inhibits the blood-brain barrier transport of choline. Ann Neurol. 1978 Oct;4(4):302-6. doi: 10.1002/ana.410040403. PMID: 727735. ↥ ↥
Haubrich DR, Wang PF, Clody DE, Wedeking PW (1975): Increase in rat brain acetylcholine induced by choline or deanol. Life Sci. 1975 Sep 15;17(6):975-80. doi: 10.1016/0024-3205(75)90451-8. PMID: 1195991. ↥
Rosen MA, Jones RM, Yano Y, Budinger TF (1985): Carbon-11 choline: synthesis, purification, and brain uptake inhibition by 2-dimethylaminoethanol. J Nucl Med. 1985 Dec;26(12):1424-8. PMID: 3877796. ↥
Flood JF, Smith GE, Cherkin A (1983): Memory retention: potentiation of cholinergic drug combinations in mice. Neurobiol Aging. 1983 Spring;4(1):37-43. doi: 10.1016/0197-4580(83)90052-0. PMID: 6877486. ↥ ↥ ↥
Bevan C, Kinne RK (1990): Choline transport in collecting duct cells isolated from the rat renal inner medulla. Pflugers Arch. 1990 Nov;417(3):324-8. doi: 10.1007/BF00370999. PMID: 2274417. ↥
Naujokaitis SA, Fisher JM, Rabinovitz M (1984): Protection of murine L1210 leukemia and bone marrow progenitor cells against mechlorethamine and inhibition of choline uptake as a structure-activity relationship of 2-dimethylaminoethanol and its analogues. J Pharm Sci. 1984 Jan;73(1):34-9. doi: 10.1002/jps.2600730109. PMID: 6694079. ↥
Shimon M, Egozi Y, Kloog Y, Sokolovsky M, Cohen S (1988): Kinetics of choline uptake into isolated rat forebrain microvessels: evidence of endocrine modulation. J Neurochem. 1988 Jun;50(6):1719-24. doi: 10.1111/j.1471-4159.1988.tb02469.x. PMID: 3373211. ↥
Haubrich DR, Gerber N, Pflueger AB, Zweig M (1981): Tissue choline studied using a simple chemical assay. J Neurochem. 1981 Apr;36(4):1409-17. doi: 10.1111/j.1471-4159.1981.tb00580.x. PMID: 7264637. ↥
Haubrich DR, Wang PF, Chippendale T, Proctor E (1976): Choline and acetylcholine in rats: effect of dietary choline. J Neurochem. 1976 Dec;27(6):1305-13. doi: 10.1111/j.1471-4159.1976.tb02608.x. PMID: 1003204. ↥
Goldstein (1960): Electroencephalographic analysis of the effect of 2-dimethylaminoethanol, choline and atropine on the rabbit brain. Pharmacol Exp Ther. 1960 Apr:128:392-6. PMID: 13850775 ↥ ↥
Kostopoulos GK, Phillis JW (1975): The effects of dimethylaminoethanol (deanol) on cerebral cortical neurons. Psychopharmacol Commun. 1975;1(3):339-47. PMID: 1224003. ↥
Gramatté T, Wustmann C, Schmidt J, Fischer HD (1986): Effects of nootropic drugs on some behavioural and biochemical changes after early postnatal hypoxia in the rat. Biomed Biochim Acta. 1986;45(8):1075-82. PMID: 3778435. ↥
Christensen AV, Nielsen IM (1979): Dopaminergic supersensitivity: influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia. Psychopharmacology (Berl). 1979 Apr 11;62(2):111-6. doi: 10.1007/BF00427122. PMID: 111273. ↥
Jacobs TQ, Passarello B, Horwitz J (1998): Increased levels of methylated intermediates of phosphatidylcholine lead to enhanced phospholipase D activity. Neurochem Res. 1998 Aug;23(8):1099-105. doi: 10.1023/a:1020716304520. PMID: 9704600. ↥
Lohr J, Acara M (1990): Effect of dimethylaminoethanol, an inhibitor of betaine production, on the disposition of choline in the rat kidney. J Pharmacol Exp Ther. 1990 Jan;252(1):154-8. PMID: 2405150. ↥ ↥
ARTOM C, CORNATZER WE (1948): The action of ethanolamine, methylethanolamine, and dimethylethanolamine on lipide phosphorylation. J Biol Chem. 1948 Nov;176(2):949-59. PMID: 18889949. ↥
Woolverton WL, Balster RL (1982): Behavioral pharmacology of local anesthetics: reinforcing and discriminative stimulus effects. Pharmacol Biochem Behav. 1982 Mar;16(3):491-500. doi: 10.1016/0091-3057(82)90458-0. PMID: 7079285. ↥
Yao ZM, Vance DE (1989): Head group specificity in the requirement of phosphatidylcholine biosynthesis for very low density lipoprotein secretion from cultured hepatocytes. J Biol Chem. 1989 Jul 5;264(19):11373-80. PMID: 2738069. ↥
Semsei I, Zs-Nagy I (1985): Superoxide radical scavenging ability of centrophenoxine and its salt dependence in vitro. J Free Radic Biol Med. 1985;1(5-6):403-8. doi: 10.1016/0748-5514(85)90153-9. PMID: 3018064. ↥
Fisher MC, Zeisel SH, Mar MH, Sadler TW (2002): Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro. FASEB J. 2002 Apr;16(6):619-21. doi: 10.1096/fj.01-0564fje. PMID: 11919173. ↥
Güleç A, Türkoğlu S, Kocabaş R (2024): The relationship between sphingomyelin and ceramide levels and soft neurological signs in ADHD. J Neural Transm (Vienna). 2024 Sep 9. doi: 10.1007/s00702-024-02831-w. PMID: 39249516. ↥
Moeckel GW, Lien YH (1997): Distribution of de novo synthesized betaine in rat kidney: role of renal synthesis on medullary betaine accumulation. Am J Physiol. 1997 Jan;272(1 Pt 2):F94-9. doi: 10.1152/ajprenal.1997.272.1.F94. PMID: 9039054. ↥
Houston KM, Babayan SA, Allen JE, Harnett W (2008): Does Litomosoides sigmodontis synthesize dimethylethanolamine from choline? Parasitology. 2008 Jan;135(Pt 1):55-61. doi: 10.1017/S0031182007003642. PMID: 17892618. ↥
Haubrich DR, Gerber NH, Pflueger AB (1981): Deanol affects choline metabolism in peripheral tissues of mice. J Neurochem. 1981 Aug;37(2):476-82. doi: 10.1111/j.1471-4159.1981.tb00480.x. PMID: 7264671. ↥
Alvaro D, Cantafora A, Gandin C, Masella R, Santini MT, Angelico M (1989): Selective hepatic enrichment of polyunsaturated phosphatidylcholines after intravenous administration of dimethylethanolamine in the rat. Biochim Biophys Acta. 1989 Nov 6;1006(1):116-20. doi: 10.1016/0005-2760(89)90331-7. PMID: 2804062. ↥
Malewicz B, Mukherjee JJ, Crilly KS, Baumann WJ, Kiss Z (1998): Phosphorylation of ethanolamine, methylethanolamine, and dimethylethanolamine by overexpressed ethanolamine kinase in NIH 3T3 cells decreases the co-mitogenic effects of ethanolamines and promotes cell survival. Eur J Biochem. 1998 Apr 1;253(1):10-9. doi: 10.1046/j.1432-1327.1998.2530010.x. PMID: 9578455. ↥
Stenbäck F, Weisburger JH, Williams GM (1988): Effect of lifetime administration of dimethylaminoethanol on longevity, aging changes, and cryptogenic neoplasms in C3H mice. Mech Ageing Dev. 1988 Feb;42(2):129-38. doi: 10.1016/0047-6374(88)90068-1. PMID: 3361965. ↥
Gragnani A, Giannoccaro FB, Sobral CS, Moraes AA, França JP, Ferreira AT, Ferreira LM (2007): Dimethylaminoethanol affects the viability of human cultured fibroblasts. Aesthetic Plast Surg. 2007 Nov-Dec;31(6):711-8. doi: 10.1007/s00266-006-0208-3. Erratum in: Aesthetic Plast Surg. 2008 Mar;32(2):406. Moraes, A A F [added]; Ferreira, A T [added]. PMID: 17940822. ↥
Kiss Z, Crilly KS (1996): Ethanolamine analogues stimulate DNA synthesis by a mechanism not involving phosphatidylethanolamine synthesis. FEBS Lett. 1996 Feb 26;381(1-2):67-70. doi: 10.1016/0014-5793(96)00084-1. PMID: 8641441. ↥
Abebe W, Maddux WF, Schuster GS, Lewis JB (2003): Vascular responsiveness to dimethylaminoethyl methacrylate and its degradation products. J Biomed Mater Res A. 2003 Jul 1;66(1):155-61. doi: 10.1002/jbm.a.10568. PMID: 12833442. ↥
Blin O, Audebert C, Pitel S, Kaladjian A, Casse-Perrot C, Zaim M, Micallef J, Tisne-Versailles J, Sokoloff P, Chopin P, Marien M (2009): Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. Psychopharmacology (Berl). 2009 Dec;207(2):201-12. doi: 10.1007/s00213-009-1648-7. PMID: 19756528. ↥
Costa LG, Murphy SD (1984): Interaction of choline with nicotinic and muscarinic cholinergic receptors in the rat brain in vitro. Clin Exp Pharmacol Physiol. 1984 Nov-Dec;11(6):649-54. doi: 10.1111/j.1440-1681.1984.tb00878.x. PMID: 6536422. ↥ ↥
Oettinger L Jr (1958): The use of deanol in the treatment of disorders of behavior in children. J Pediatr. 1958 Dec;53(6):671-5. doi: 10.1016/s0022-3476(58)80302-9. PMID: 13599085. n = 108 ↥ ↥ ↥
OETTINGER L Jr (1955): Meratran; preliminary report of a new drug for the treatment of behavior disorders in children. Dis Nerv Syst. 1955 Oct;16(10):299-302. PMID: 13261892. ↥ ↥ ↥
GELLER SJ (1960): Comparison of a tranquilizer and a psychic energizer used in treatment of children with behavioral disorders. JAMA. 1960 Oct 1;174:481-4. doi: 10.1001/jama.1960.03030050023006. PMID: 13827210. n = 75 ↥ ↥ ↥ ↥
Silbergeld EK, Goldberg AM (1975): Pharmacological and neurochemical investigations of lead-induced hyperactivity. Neuropharmacology. 1975 May-Jun;14(5-6):431-44. doi: 10.1016/0028-3908(75)90026-x. PMID: 1171389. ↥
Knobel, M.: Two-dimethylaminoethanol in behavior problems of children. Sem. Med. (B. Air.), 119(24):939-944,196, zitiert nach Coleman N, Dexheimer P, DiMascio A, Redman W, Finnerty R (1976): Deanol in the treatment of hyperkinetic children. Psychosomatics. 1976;17(2):68-72. doi: 10.1016/S0033-3182(76)71146-0. PMID: 781713. ↥
Karoly A J, Love, W (1965): Deanol effects on learning a complex maze in rats. Proceedings of the Annual Convention of the American Psychological Association, 123–124. ↥
Udabe, R.L. (1964): Clinical experience with 2-dimethylaminoethanol in the psychopharmacology of children. Read at the Third Latin American Congress of Psychiatry, Lima, Peru, October 25-31, 1964, zitiert nach Coleman N, Dexheimer P, DiMascio A, Redman W, Finnerty R (1976): Deanol in the treatment of hyperkinetic children. Psychosomatics. 1976;17(2):68-72. doi: 10.1016/S0033-3182(76)71146-0. PMID: 781713. ↥
BOSTOCK J, SHACKLETON M (1962): The use of DMAE (“Deaner”) in behaviour states. Med J Aust. 1962 Sep 1;49(2):337-9. doi: 10.5694/j.1326-5377.1962.tb20277.x. PMID: 14014225. ↥ ↥ ↥
The Use of Deanol for Attention Deficit-Hyperactive Disorder; 최신의학 1988년 31권 7호 p.131 ~ 134; KMID : 0378019880310070131 ↥
Kugel R B, Alexander T (1963): THE EFFECT OF A CENTRAL NERVOUS SYSTEM STIMULANT (DEANOL) ON BEHAVIOR; Pediatrics (1963) 31 (4): 651–655.https://doi.org/10.1542/peds.31.4.651 n = 42 ↥
MURPHREE HB Jr, PFEIFFER CC, BACKERMAN IA (1960): The stimulant effect of 2-dimethylaminoethanol (deanol) in human volunteer subjects. Clin Pharmacol Ther. 1960 May-Jun;1:303-10. doi: 10.1002/cpt196013303. PMID: 14425373. ↥
Conners, C.K. (1973): Deanol and behavior disorders in children: a critical review of the literature and recommended future studies for determining efficacy. Psychopharm. Bull. (Special Issue) pp. 188-195, 1973, zitiert nach Coleman N, Dexheimer P, DiMascio A, Redman W, Finnerty R (1976): Deanol in the treatment of hyperkinetic children. Psychosomatics. 1976;17(2):68-72. doi: 10.1016/S0033-3182(76)71146-0. PMID: 781713. ↥
Millichap JG, Fowler GW (1967): Treatment of “minimal brain dysfunction” syndromes. Selection of drugs for children with hyperactivity and learning disabilities. Pediatr Clin North Am. 1967 Nov;14(4):767-77. doi: 10.1016/s0031-3955(16)32054-5. PMID: 4875461. REVIEW ↥
Coleman N, Dexheimer P, DiMascio A, Redman W, Finnerty R (1976): Deanol in the treatment of hyperkinetic children. Psychosomatics. 1976;17(2):68-72. doi: 10.1016/S0033-3182(76)71146-0. PMID: 781713. ↥
Shipilova EM, Zavadenko NN, Nesterovskiy YE (2016): Vozmozhnosti profilakticheskoi terapii pri golovnoi boli napryazheniya u detei i podrostkov [Possibilities of preventive treatment of tension-type headache in children and adolescents]. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(4 Pt 2):31-36. Russian. doi: 10.17116/jnevro20161163231-36. PMID: 27456718. ↥ ↥
Settel E (1959): Stimulant therapy with deanol in depression, migraine, and tension headaches. J Am Geriatr Soc. 1959 Nov;7:877-9. doi: 10.1111/j.1532-5415.1959.tb00358.x. PMID: 14445203. n = 77 ↥
DOMINIAN J (1960): Deanol in depression. A controlled trial. J Ment Sci. 1960 Apr;106:711-2. doi: 10.1192/bjp.106.443.711. PMID: 13817409. n = 20 ↥
Agibalova TV, Buzik OZ, Rychkova OV, Smyshlyaev AV, Rumbesht VV (2018): Dinamika simptomov sindroma otmeny alkogolia v protsesse lecheniia nooklerinom (deanola atseglumat) [Alcohol withdrawal syndrome dynamics during treatment with nooclerin (deanoli aceglumas)]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(1. Vyp. 2):45-51. Russian. doi: 10.17116/jnevro20181181245-51. PMID: 29658504. ↥
Shipilova EM, Nesterovsky YE (2019): Vliianie nooklerina na strukturu narusheniĭ sna u deteĭ s golovnymi boliami napriazheniia [The influence of nooclerin on the structure of sleep disturbances in children with tension headaches]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(11):41-46. Russian. doi: 10.17116/jnevro201911911141. PMID: 31851171. ↥
Smulevich AB, Chitlova VV, Germanova KN (2017): Opyt primeneniia nooklerina (deanola atseglumat) pri terapii kognitivnykh i astenicheskikh rasstroĭstv u bol’nykh s pogranichnoĭ psikhicheskoĭ patologieĭ [Nooklerin (deanoli aceglumas) in the treatment of astenic and cognitive disorders in patients with borderline psychopatological conditions]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(9):31-36. Russian. doi: 10.17116/jnevro20171179131-36. PMID: 29053118. n = 60 ↥
Chutko LS, Kornishina TL, Surushkina SY, Yakovenko EA, Anisimova TI, Volov MB (2018): Sindrom vegetativnoĭ disfunktsii u deteĭ i podrostkov [Syndrome of autonomic dysfunction in children and adolescents]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(1):43-49. Russian. doi: 10.17116/jnevro20181181143-49. PMID: 29460904. ↥
Chutko A V, Surushkina S Yu, Nikishena I S, Yakovenko E A, Anisimova T I (2013): DEANOL ACEGLUMATE IN NEURASTHENIA TREATMENT IN ADOLESCENTS WITH SCHOOL DISADAPTATION. Current Pediatrics. 2013;12(5):99-103. (In Russ.) https://doi.org/10.15690/vsp.v12i5.806 ↥
Blinov DS, Gogina ED, Krupnova TS, Balashov VP, blinova EV, Sadovnikov VN, Lebedev AB, Nikitina OI (2012): [Hepatoprotective effect of deanol aceglumate on experimental stress-induced gastropathy and diabetes mellitus]. Eksp Klin Farmakol. 2012;75(4):17-9. Russian. PMID: 22702105. ↥
Sergio W (1988): Use of DMAE (2-dimethylaminoethanol) in the induction of lucid dreams. Med Hypotheses. 1988 Aug;26(4):255-7. doi: 10.1016/0306-9877(88)90129-6. PMID: 3173167. ↥
Davydova NG, Kuznetsova TP, Borisova SA, Abdulkadyrova MZh (2006): [Effects of nootropic agents on visual functions and lacrimal antioxidative activity in patients with primary open-angle glaucoma]. Vestn Oftalmol. 2006 Nov-Dec;122(6):42-5. Russian. PMID: 17217203. ↥
CRONHEIM GE, TOEKES IM (1959): The effect of 2-dimethylaminoethanol (deanol) on anaphylactoid edema in rats. J Pharmacol Exp Ther. 1959 Oct;127:167-70. PMID: 13812963. ↥
Grossman R (2005): The role of dimethylaminoethanol in cosmetic dermatology. Am J Clin Dermatol. 2005;6(1):39-47. doi: 10.2165/00128071-200506010-00005. PMID: 15675889. REVIEW ↥
Morissette G, Germain L, Marceau F (2007): The antiwrinkle effect of topical concentrated 2-dimethylaminoethanol involves a vacuolar cytopathology. Br J Dermatol. 2007 Mar;156(3):433-9. doi: 10.1111/j.1365-2133.2007.07681.x. PMID: 17300230. ↥
Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K (2004): Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1099-107. doi: 10.1016/j.pnpbp.2004.05.045. PMID: 15610922. REVIEW ↥
PORTNOW SL, ARDIS MB, LUBACH JE (1960): The effect of deanol on the activity of chronic schizophrenic patients. Am J Psychiatry. 1960 Feb;116:748-9. doi: 10.1176/ajp.116.8.748. PMID: 14434330. ↥
Fisman M, Mersky H, Helmes E (1981): Double-blind trial of 2-dimethylaminoethanol in Alzheimer’s disease. Am J Psychiatry. 1981 Jul;138(7):970-2. doi: 10.1176/ajp.138.7.970. PMID: 7020434. ↥
Caffarra P, Cattelani R, Mazzucchi A, Moretti G, Parma M (1980): Gli effetti del Deanol nelle sindromi amnesiche. Dati preliminari [The effect of Deanol on amnesic disorders. A preliminary trial (author’s transl)]. Ateneo Parmense Acta Biomed. 1980;51(4):383-9. Italian. PMID: 7470191. ↥
Deanol: Anvendelser, bivirkninger, interaktioner, dosering og advarsel dansk ↥
Katyal SL, Lombardi B (1978): Effects of dietary choline and N,N-dimethylaminoethanol on lung phospholipid and surfactant of newborn rats. Pediatr Res. 1978 Sep;12(9):952-5. doi: 10.1203/00006450-197809000-00014. PMID: 251230. ↥
PFEIFFER CC, GOLDSTEIN L, MURPHREE HB, SUGERMAN AA (1965): TIME-SERIES, FREQUENCY ANALYSIS, AND ELECTROGENESIS OF THE EEGS OF NORMALS AND PSYCHOTICS BEFORE AND AFTER DRUGS. Am J Psychiatry. 1965 Jun;121:1147-55. doi: 10.1176/ajp.121.12.1147. PMID: 14286047. ↥
Fisher MC, Zeisel SH, Mar MH, Sadler TW (2001): Inhibitors of choline uptake and metabolism cause developmental abnormalities in neurulating mouse embryos. Teratology. 2001 Aug;64(2):114-22. doi: 10.1002/tera.1053. PMID: 11460263. ↥
DocCheck Flexikon: Betain german ↥
Haug BA, Holzgraefe M (1991): Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol)? Eur Neurol. 1991;31(6):423-5. doi: 10.1159/000116708. PMID: 1756771. ↥